A phase I/II study of HLX301, a recombinant humanized anti-PDL1 and anti-TIGIT bispecific antibody, is currently enrolling patients with advanced solid tumors, including NSCLC (NCT05390528). This evidence concerns the gene TIGIT and non-small cell lung carcinoma.